

ANDREW M. CUOMO Governor **HOWARD A. ZUCKER, M.D., J.D.**Acting Commissioner

SALLY DRESLIN, M.S., R.N.Executive Deputy Commissioner

Medicaid Fee- for- Service Providers Dispense Brand Name Drug when Less Expensive than Generic Program

Effective 4/20/2017, the following changes will be made to the Dispense Brand Name Drug when Less Expensive than Generic Program:

- Benzaclin gel will be <u>added</u> to the program.
- Niaspan, Astepro, Baraclude and Epivir HBV will be removed from the program.

In conformance with State Education Law which intends that patients receive the lower cost alternative, brand name drugs included in this program:

- Do not require 'Dispense as Written' (DAW) or 'Brand Medically Necessary' on the prescription.
- Have a generic copayment.
- Are paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (SMAC/FUL are not applied).
- Do not require a new prescription if the drug is removed from this program.

IMPORTANT BILLING INFORMATION

Prescription claims submitted to the Medicaid program **do not require** the submission of Dispense as Written/Product Selection Code of '1'; **Pharmacies can submit any valid NCPDP field (408-D8) value.**

List of Brand Name Drugs included in this program* (Updated): 4/3/2017

Adderall XR	Exelon Patch	Seroquel XR
Aggrenox	Focalin XR	Tegretol suspension
Alphagan P 0.15%	Gleevec	Tegretol XR
Benzaclin pump, gel	Hepsera	Tobradex suspension
Catapres-TTS	Kapvay	Trizivir
Cellcept suspension	Myfortic	Valcyte tablet, solution
Copaxone 20mg SQ	Patanase	Voltaren Gel
Diastat	Protopic	Xeloda
Differin	Pulmicort Respules	Xenazine
Edecrin	Retin-A cream, gel	

^{*}List is subject to change

Please keep in mind that drugs in this program may be subject to prior authorization requirements of other pharmacy programs, promoting the use of the most cost-effective product.